Antoine Lecoeur, Rita-Maria Sfeir, Laura Gerard, Myriam Souifi, Johanna Damour, Catherine Lombard-Bohas, Laurent Francois, Justine Fort, Daphne Delsart, Julien Forestier, Thomas Walter, Alice Durand, Laurence Chardon
{"title":"Serum and Urinary 5-hydroxyindolacetic acid, Serotonin, Chromogranin A, and NT-proBNP for the detection of Carcinoid Heart Disease.","authors":"Antoine Lecoeur, Rita-Maria Sfeir, Laura Gerard, Myriam Souifi, Johanna Damour, Catherine Lombard-Bohas, Laurent Francois, Justine Fort, Daphne Delsart, Julien Forestier, Thomas Walter, Alice Durand, Laurence Chardon","doi":"10.1093/ejendo/lvae150","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).</p><p><strong>Design: </strong>An explorative ancillary study of the French CrusoeNET cohort.</p><p><strong>Methods: </strong>Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS and/or elevation of u5HIAA twice greater than the upper limit of normal. All patients included had one available serum stored within the local biobank between January 2021 and April 2022. Echocardiography was performed by one of the three expert cardiologists of the Lyon- EURACAN-CoE.</p><p><strong>Results: </strong>We included 138 patients with NETs, mainly of the small intestine and lung, 19 of them had a CHD. Analysis showed that s5HIAA was well correlated with urinary 5-HIAA (u5HIAA, ρ=0.824 [0.76-0.88], p<0.0001), and was a good biomarker for CHD detection (AUROC=0.85 [0.75-0.94], p<0.0001). Using a threshold value of 757 nmol/L, the sensitivity and specificity for the detection of CHD were 84% and 80%, respectively.</p><p><strong>Conclusion: </strong>s5HIAA is highly sensitive and specific for CHD detection. It could be used as a pre-screening tool in centres where systematic and regular echocardiography by an expert cardiologist is not performed in this population.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvae150","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).
Design: An explorative ancillary study of the French CrusoeNET cohort.
Methods: Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS and/or elevation of u5HIAA twice greater than the upper limit of normal. All patients included had one available serum stored within the local biobank between January 2021 and April 2022. Echocardiography was performed by one of the three expert cardiologists of the Lyon- EURACAN-CoE.
Results: We included 138 patients with NETs, mainly of the small intestine and lung, 19 of them had a CHD. Analysis showed that s5HIAA was well correlated with urinary 5-HIAA (u5HIAA, ρ=0.824 [0.76-0.88], p<0.0001), and was a good biomarker for CHD detection (AUROC=0.85 [0.75-0.94], p<0.0001). Using a threshold value of 757 nmol/L, the sensitivity and specificity for the detection of CHD were 84% and 80%, respectively.
Conclusion: s5HIAA is highly sensitive and specific for CHD detection. It could be used as a pre-screening tool in centres where systematic and regular echocardiography by an expert cardiologist is not performed in this population.
研究目的本研究旨在评估不同生物标志物在检测神经内分泌肿瘤（NET）类癌性心脏病（CHD）方面的性能，尤其是血清5-HIAA（s5HIAA）：设计：法国克鲁索NET队列的一项探索性辅助研究：里昂-欧洲癌症研究中心（Lyon-EURACAN Center of Excellence，CoE）收治的患者中，年龄至少在 18 岁以上、因晚期/转移性回肠或肺部 NET 接受治疗并接受随访的患者均被纳入研究范围。所有纳入的患者均在 2021 年 1 月至 2022 年 4 月期间在当地生物库中储存了一份可用血清。超声心动图检查由里昂-EURACAN-CoE的三位心脏病专家之一进行：我们纳入了 138 名 NET 患者，主要是小肠和肺部 NET 患者，其中 19 人患有先天性心脏病。分析表明，s5HIAA与尿液中的5-HIAA（u5HIAA，ρ=0.824 [0.76-0.88]，p结论：s5HIAA对CHD检测具有高度敏感性和特异性。在没有由心脏病专家进行系统和定期超声心动图检查的中心，可将其作为预筛工具。
期刊介绍：
European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica.
The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology.
Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials.
Equal consideration is given to all manuscripts in English from any country.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
